Tomnah Ali Mohammed Alamodi; Hatem A. M. Saleh; Fahd Mohammed Abdullah Makhsham; Rasha Kadoun; Yong Feng Chen
Abstract
Psoriasis, a chronic inflammatory skin disease, has been increasingly associated with diabetes mellitus (DM), suggesting shared pathophysiological mechanisms between the two conditions. ...
Read More
Psoriasis, a chronic inflammatory skin disease, has been increasingly associated with diabetes mellitus (DM), suggesting shared pathophysiological mechanisms between the two conditions. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, has emerged as a promising treatment option for psoriatic arthritis and psoriasis, and recent studies have explored its potential benefits in patients with diabetes. This review provides a thorough investigation of the current literature on apremilast's mechanism of action, pharmacokinetics, therapeutic potential, and safety in psoriasis management, particularly in patients with diabetes. Studies have shown that apremilast's PDE4 inhibition leads to increased cAMP levels, which may improve metabolic inflammation and insulin resistance. Observational studies have also indicated the potential benefits of apremilast in managing insulin resistance among psoriasis patients. In addition, drug interaction studies have shed light on the effects of co-administering apremilast with other substances, emphasizing the importance of cautious prescribing. In conclusion, apremilast holds promise as a powerful and secure treatment option for psoriasis patients, with potential benefits in managing insulin resistance in patients with diabetes. Further research and larger clinical trials are needed to validate and expand upon these findings, paving the way for more personalized and effective therapeutic approaches.
